Last reviewed · How we verify
IV Furosemide and IV Acetazolamide
This combination uses furosemide (a loop diuretic) to increase urine output and acetazolamide (a carbonic anhydrase inhibitor) to promote bicarbonate and electrolyte excretion, together enhancing diuresis and reducing fluid overload.
This combination uses furosemide (a loop diuretic) to increase urine output and acetazolamide (a carbonic anhydrase inhibitor) to promote bicarbonate and electrolyte excretion, together enhancing diuresis and reducing fluid overload. Used for Acute decompensated heart failure with fluid overload, Resistant edema, Pulmonary edema.
At a glance
| Generic name | IV Furosemide and IV Acetazolamide |
|---|---|
| Also known as | Oral Magnesium citrate 600mg |
| Sponsor | Rambam Health Care Campus |
| Drug class | Loop diuretic and carbonic anhydrase inhibitor combination |
| Target | Na-K-2Cl cotransporter (furosemide); carbonic anhydrase (acetazolamide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Nephrology |
| Phase | FDA-approved |
Mechanism of action
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium and chloride and producing potent diuresis. Acetazolamide inhibits carbonic anhydrase in the proximal tubule, reducing bicarbonate reabsorption and promoting sodium and water excretion. Together, they provide synergistic diuretic and natriuretic effects, often used in resistant edema or acute decompensated heart failure.
Approved indications
- Acute decompensated heart failure with fluid overload
- Resistant edema
- Pulmonary edema
Common side effects
- Hypokalemia
- Hyponatremia
- Metabolic alkalosis
- Ototoxicity (furosemide)
- Metabolic acidosis (acetazolamide)
- Dehydration
- Hyperuricemia
Key clinical trials
- Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma (PHASE1)
- Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients (NA)
- EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) (NA)
- Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients (PHASE3)
- Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload (PHASE4)
- The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study (PHASE4)
- Efficacy of Oral Acetazolamide in Decongestion in Patients With Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |